Report 83: 23% of Vaccinated Mothers’ Fetuses or Neonates Died. Suppressed Lactation and Breast Milk Discoloration Reported.

The War Room/DailyClout Pfizer Documents Analysis Project Post-Marketing Group (Team 1) – Barbara Gehrett, MD; Joseph Gehrett, MD; Chris Flowers, MD; and Loree Britt – wrote a shocking analysis of the “Use in Pregnancy and Lactation” section found in Pfizer document 5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-FEB-2021 (a.k.a., “5.3.6“).  This section includes three types or groups of cases:

• Pregnancy cases
• Breast feeding baby cases
• Breast feeding mother cases

In all, 274 pregnancy cases were reported, which includes 270 mother cases and four fetus/baby cases.

It is important to note that the information in the 5.3.6 document was reported to Pfizer for only a 90-day period starting on December 1, 2020, the date of the United Kingdom’s public rollout of Pfizer’s COVID-19 experimental mRNA “vaccine” product.

Important points from this report include:

• Pfizer’s BNT162b2 mRNA COVID vaccine was not recommended for use in pregnancy or with lactation during the time of this post-marketing data set.
  • The Centers for Disease Control and Prevention (CDC) did recommend COVID vaccination for pregnant and lactating women until April 23, 2021. [https://www.verywellhealth.com/pregnant-women-covid-vaccine-5092509]
• Two hundred and seventy (270) pregnant women reported either “exposure” (146) or “vaccination” (124).
  • Exposure can mean unvaccinated women exposed to a vaccinated partner or exposed via inhalation or skin exposure to the vaccine.
  • Only a few “exposure cases” noted the timing of exposure during their pregnancies: 15 in the first trimester, seven in the second trimester, and two in the third trimester.
  • The timing of vaccination during the pregnancy was reported in just 22 of the 124 cases – 19 during the first trimester, one in the second trimester, and two in the third trimester.
    • In this group, 49 cases were rated non-serious, and 75 rated serious.
    • One mother had uterine contraction during pregnancy, and another had premature rupture of membranes.
• Twenty-eight deaths of either a fetus or neonate happened to women in the vaccinated group (124 women). So, 23% of the vaccinated mothers had fetuses or newborns who died.
  • These “losses” were described as spontaneous abortion (miscarriage) or various other terms which mean death of the fetus or baby.
• No outcome or “outcome pending” was reported for 243 of the 274, or 88.7%, of the pregnancy cases.
  • Because of this, it is unknown if 243 of the pregnancy cases resulted in normal or abnormal outcomes.
  • Only 11.3% of pregnancies had known outcomes.
• There were five serious clinical events in four babies: two fetal growth retardation, two premature babies, and one neonatal death.
• Four breast feeding mothers reported suppressed lactation, one of which was considered serious and also involved “paresis,” a weakness (less than complete paralysis) usually of an arm or leg.
• Breast milk discoloration was also reported by breast feeding mothers.
• Clinical events were only listed if they occurred in more than five cases. How many in this important section went unreported?
  •  Many non-serious and serious were not separated but reported together, so it is unknown which of the following symptoms or combination of symptoms were responsible for the remaining 40+ serious clinical cases:
    • Thirty-three (33) headache, 24 vaccination site pain, 22 pain in extremity, 22 fatigue, 16 myalgia (muscle aches), 16 pyrexia (fever), 13 chills, 12 nausea, 11 pain, nine arthralgia (joint aches), seven lymphadenopathy (swollen lymph nodes), six chest pain, six dizziness, six asthenia (weakness or lack of energy), and five malaise.
    • Two other clinical events were included: seven drug ineffective (defined as getting COVID between 14 days after the first shot and six days after the second shot) and five COVID-19 (presumably infection more than a week after the second injection, in other words failure of full immunization).
• One hundred and thirty-three (133) breast feeding baby cases were reported.
  • One hundred and sixteen (116) simply reported exposure but no adverse reaction.
  • Seventeen (17) adverse reactions were reported, three classified as serious and 14 as non-serious.
    • Breast feeding babies’ reactions included:
      • Pyrexia (fever), rash, infant irritability, infantile vomiting, diarrhea, insomnia, illness, poor feeding infant, lethargy, abdominal discomfort, vomiting, allergy to vaccine, increased appetite, anxiety, crying, poor quality sleep, eructation (burping), agitation, pain, and urticaria (hives).
• There is a stark contrast in the cases shown in Pfizer’s Pregnancy and Lactation Cumulative Review and the pregnancy and lactation cases reported in 5.3.6, which is surprising given that the bulk of inoculations reflected in the Cumulative Review likely occurred during the period of time included in 5.3.6.
  • Pfizer’s Cumulative Report documents 53 spontaneous abortions and two premature births with neonatal death, compared to 26 and two, respectively, documented in 5.3.6.
  • Pfizer’s Cumulative Report reported 41 baby/infant cases exposed via breastmilk who had adverse events, with 10 of the cases experiencing serious adverse events. Yet, the comparable figures from 5.3.6 Table 6 were 17 cases and three serious cases.
  • Why are there twice as many spontaneous abortions in Pfizer’s Cumulative Report? Why does the Cumulative Report have so many more baby cases with adverse and serious adverse events?

Please read the full report below.

p1 Post Marketing Team Pregnancy Lactation MicroReport

https://dailyclout.io/wp-content/uploads/p1-Post-Marketing-Team-Pregnancy-Lactation-MicroReport.pdf

p2 Post Marketing Pregnancy Lactation MicroReport

https://dailyclout.io/wp-content/uploads/p2-Post-Marketing-Pregnancy-Lactation-MicroReport.pdf

p3 Post Marketing Pregnancy Lactation MicroReport

https://dailyclout.io/wp-content/uploads/p3-Post-Marketing-Pregnancy-Lactation-MicroReport.pdf